Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 12,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Overactive Bladder
Interventions: (VERV™ System), Sham version of (VERV™ System); Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more

Conditions: Brain Neoplasm, Lymphoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions: Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Penguin Cold Cap; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, Multiple Myeloma
Interventions: CMV-MVA Triplex Vaccine; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Progressive Multiple Sclerosis
Interventions: Obecabtagene autoleucel (obe-cel); Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Migraine
Interventions: Nerivio active device, Nerivio sham device; Device
Lead sponsor: Theranica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Carlsbad, California • Newport Beach, California + 13 more

Conditions: Hodgkin's Lymphoma, Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions: Nestle Impact Advanced Recovery; Dietary Supplement
Lead sponsor: Greg Monohan; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Asthma
Interventions: Mepolizumab; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: Long Beach, California • Newport Beach, California • Riverside, California + 16 more

Conditions: Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: filgrastim, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Impotence
Interventions: sildenafil citrate, placebo for sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Huntsville, Alabama • San Diego, California • Aurora, Colorado + 17 more

Conditions: Non-inflammatory Degenerative Joint Disease
Interventions: ASR™-XL Modular Acetabular Cup System, Pinnacle™ acetabular shell; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 8
States / cities: Rancho Mirage, California • Cumming, Georgia • Morton Grove, Illinois + 5 more

Conditions: Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome
Interventions: Naglazyme; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Up to 1 Year
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Los Angeles, California • Oakland, California

Conditions: Fatigue, Multiple Sclerosis, Sleep Apnea
Interventions: Auto-titration CPAP, Sham-CPAP; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: Motixafortide, G-CSF; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 78 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Vascular Disease
Interventions: ArterX Surgical Sealant, Gelfoam and Thrombin; Device
Lead sponsor: Tenaxis Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: bortezomib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gingival Recession
Interventions: Acellular Dermal Matrix; Biological
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Chronic Conditions, Disability Physical
Interventions: Behavioral Activation + Occupational Therapy, Enhanced Usual Care; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 60 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 1
States / cities: Lawrenceville, New Jersey

Conditions: Cancer of Pancreas, Pancreatic Neoplasm
Interventions: Pancreatic Biopsy, Histological Samples; Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 19 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Birmingham, Alabama • Orlando, Florida

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy Controls
Interventions: C11-SY08; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, BFF MDI 320/9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 8,588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 318
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 249 more

Conditions: Hypertension
Interventions: amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more

Search by objective public record fields.

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention

Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire

Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System

A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes

Behavioral Activation + Occupational Therapy

Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

Trial Comparing 19 and 25-gauge EUS-FNA Needles

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

PET Imaging Evaluation of [11C]SY08

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure